Articles tagged with Vaccine Development
Researchers at Karolinska Institutet and the universities of Jyväskylä and Tampere have produced a vaccine that protects against all six known strains of Coxsackie B virus, which may play a role in triggering type 1 diabetes. The vaccine was tested in animal models and showed promise, with plans to conduct human clinical trials.
A newly developed inactivated SARS-CoV-2 vaccine candidate protected macaques from infection and neutralized multiple virus strains without ADE risk. Clinical trials with the PiCoVacc are expected to begin later this year.
Researchers have developed a vaccine that protects against the Coxsackie B virus, which may play a role in triggering type 1 diabetes. The vaccine was shown to be highly immunogenic and protective in animal models and non-human primates.
Researchers identified a significant fraction of antibodies expressed by B cell plasmablasts circulating after DENV infection, particularly in individuals experiencing their first infection. This finding holds promise for developing new diagnostic tools and a safe, efficacious dengue vaccine.
Researchers are testing the effectiveness of hydroxychloroquine as a preventative therapy for COVID-19 in healthy individuals who have been exposed to infected patients. The study aims to prevent infection and symptoms, with the goal of protecting vulnerable populations and reducing transmission within households.
The University of Saskatchewan's VIDO-InterVac has been awarded $23 million to fast-track COVID-19 vaccine development. The funding will support pre-clinical testing and two phases of clinical trials, with the goal of making a safe and effective vaccine available as early as next spring.
A recent trial of a MERS coronavirus vaccine candidate has shown promising results, with the vaccine inducing antibody and T cell responses in nearly all trial subjects. The findings have implications for the development of a vaccine against SARS-CoV-2, with plans to conduct further trials.
George Mason University's National Center for Biodefense and Infectious Diseases will provide expertise and resources to Emergex in developing CD8+ priming RNA virus vaccines. These vaccines offer advantages over traditional vaccines by providing a cell-mediated immune response, reducing allergic and autoimmune side effects.
The Coalition for Epidemic Preparedness Innovations (CEPI) grants $6.9 million funding to INOVIO and IVI to conduct clinical testing in Korea for INOVIO's COVID-19 vaccine candidate based on their well-established DNA platform technology. The trial will be conducted in parallel to INOVIO's Phase I INO-4800 study underway in the US.
Researchers at the University of Texas Medical Branch have created a reverse genetic system for SARS coronavirus 2, allowing for quick development and evaluation of vaccines and diagnosis of infected patients. The system enables high-throughput testing in 12 hours, significantly reducing turnaround time compared to conventional methods.
Researchers at the Butantan Institute and Boston Children's Hospital have developed a novel pneumonia vaccine capable of providing protection against all serotypes of Streptococcus pneumoniae. The vaccine is less expensive and more effective than current vaccines, with an estimated price of $2 per dose.
The Coronavirus Immunotherapy Consortium will streamline and accelerate the development of antibody therapies against SARS-CoV-2, providing crucial insights to guide vaccine development. CoVIC brings together scientists worldwide to share and evaluate candidate antibodies in a blinded analysis.
Researchers have identified two crucial surface proteins, SpyAD and Isp2, that contribute to Group A streptococcus fitness in the female genital tract. This discovery may lead to the development of effective treatments and vaccines for puerperal sepsis.
A University of Saskatchewan research team has been awarded nearly $1 million to develop animal models and test vaccine candidates for the new coronavirus. The project aims to identify suitable animal models to replicate human disease, with a goal of developing a pan-coronavirus vaccine.
Researchers at Colorado State University have discovered how a viral protein regulates genome replication in viruses like West Nile and Zika. The study found that the protein acts as a brake during unwinding, and mutations can affect replication efficiency.
A study found that childhood vaccine responses are shaped by geography, age, and anemia status. Children with anemia showed weaker immune responses to malaria vaccines in Tanzania and Mozambique.
Researchers charted immune system development in sub-Saharan African children to improve vaccine efficacy. Their findings suggest that a child's age, location, and health status influence their immune response to vaccines.
A new experimental vaccine for African swine fever has shown promising results, with both low and high doses being 100% effective against the virus when challenged 28 days post-inoculation. The vaccine was developed to combat the highly contagious and lethal ASFV-G strain, which has been devastating Eastern Europe and Southeast Asia.
A new study shows that a Zika vaccine doesn't have to offer perfect protection to be valuable, with potential cost savings in certain situations.
The International Vaccine Institute (IVI) has renewed its partnership with Sweden's Swedish International Cooperation Agency (Sida) to accelerate vaccine research and development for global health. The five-year partnership will focus on infectious diseases of global importance, including cholera, typhoid, and dengue.
The Partnership for Research on Ebola Vaccination (PREVAC) has received additional funding to evaluate three Ebola vaccine regimens for long-term safety and durability. The PREVAC-UP project will assess these factors over 5 years after vaccination, as well as the impact of co-infections like malaria and helminths on immune responses.
A landmark study by the Global Enteric Multicenter Study (GEMS) found that even mild cases of diarrheal illness can be fatal to young children. The study, published in Lancet Global Health, suggests that more aggressive action is needed to prevent and treat all cases of diarrheal illness, regardless of severity.
The International Vaccine Institute (IVI) has received a $1.4 million grant from the Bill & Melinda Gates Foundation to develop international standards for oral cholera vaccine manufacturing. This will enable multiple manufacturers to produce low-cost vaccines, meeting global demand and ensuring uniform efficacy.
Researchers have successfully tested a new immunotherapy approach that targets brain plaque and tau protein aggregates linked to Alzheimer's disease. The treatment, developed using a combination of vaccines, shows promise for preventing dementia in humans within two years.
Researchers have developed a novel way to record patient vaccination history by storing data in a pattern of invisible dye delivered under the skin. The dye remains stable for at least five years and can be detected using a specially equipped smartphone, promising to improve vaccine administration in developing nations.
Researchers developed a Zika vaccine that safely protects both mother and fetus from the virus. However, pregnancy weakens the immune response, requiring a higher dose of vaccination to be effective.
Researchers at the University of Adelaide have made significant progress in developing a novel Zika virus vaccine that prevents infection in pre-clinical models. The vaccine's effectiveness has been demonstrated in mouse models, offering a promising solution to prevent congenital effects in infants born to infected mothers.
Researchers have developed a new biotechnology platform to produce safer 'hybrid' viruses for vaccines and diagnostics against mosquito-borne diseases. The Binjari virus, inert to humans, is used to create 'dangerous-looking' viruses like Zika and dengue that cannot grow in humans or animals.
Researchers at UMSOM are testing a combined Shigella-ETEC vaccine to offer protection against diarrheal diseases, which cause millions of deaths worldwide. The vaccine has been developed with $4.5 million funding from Emergent BioSolutions.
A new method has been developed to accelerate the development of protein therapeutics by utilizing a cell-free system for glycosylation. This approach enables researchers to quickly discover and understand glycosylation pathways, leading to faster medicine creation and potentially opening up new avenues for treating diseases.
Eastern equine encephalitis virus is a deadly mosquito-borne illness that has existed for centuries, with a particularly deadly year in the US in 2019. Current research efforts focus on developing vaccines and treatments, but challenges include limited funding and difficulties in reaching target populations.
OHSU researchers have been awarded $2.1 million to develop new adjuvants that can enhance immune responses against infectious diseases. The goal is to create a range of adjuvants that can be used with different vaccines to protect against various pathogens.
Dr. Bruce Alberts will receive the 2020 John Edward Porter Legacy Award for his commitment to scientific research and education. The award recognizes his efforts to promote science as inquiry and improve science education in primary and secondary schools.
Dr. Kathleen Neuzil's pivotal research informed global vaccine policy, saving millions worldwide. As a member of the National Academy of Medicine, she will continue to shape public health policy.
Researchers have identified promising new strategies to counteract infection and develop effective vaccines. The vaccine targets both the offending microbe and its tick carrier to prevent Lyme disease.
The study found that almost complete immune capacity in the gut had developed as early as 14 weeks, with cells from both innate and adaptive immune systems present. This discovery could lead to the development of new maternal vaccines and a better understanding of the risk of autoimmune diseases.
MIT researchers have developed a delivery system that makes RNA vaccines more powerful, triggering efficient protein production and boosting immune response. The nanoparticles also activate an immune signaling pathway, provoking T cells to attack cancer cells and infectious agents.
The US FDA has approved a new smallpox vaccine called JYNNEOS, which is non-replicating and can be used to protect against both smallpox and monkeypox diseases. The vaccine developed by Bavarian Nordic was shown to have a superior immune response compared to the existing ACAM2000 vaccine.
A new type of vaccine that can be stored at warmer temperatures has been developed for Chikungunya, a disease that causes crippling headache and joint pain. The vaccine candidate has shown exceptionally promising results in animal studies, setting the stage for a future vaccine to combat the disease.
Replacing seasonal vaccines with universal ones could avert over 17 million cases and 251,000 hospitalizations per year. States with high hospitalization costs and elderly populations would experience the greatest economic benefits.
Researchers at Penn Medicine have developed a vaccine that protects against genital herpes, with almost all animal subjects exposed to the virus showing sterilizing immunity. The vaccine stimulates three types of antibodies to block the virus from entering cells and ensure innate immune system protective functions are not turned off.
The University of Maryland School of Medicine has been awarded a $200 million contract from the National Institute of Allergy and Infectious Diseases to develop and test new influenza vaccines. The research aims to protect against emerging flu strains and improve seasonal vaccines.
A recent study reveals that dengue virus mutations in its E protein can render vaccines and treatments ineffective. The findings also suggest that lab-adapted strains may not accurately represent clinical strains, highlighting the need for further research.
A Wistar team is advancing a synthetic DNA technology called DNA-encoded monoclonal antibodies (DMAbs) to combat multidrug-resistant Pseudomonas aeruginosa. The researchers have demonstrated the effectiveness of DMAbs in controlling infection in mice, paving the way for further development and clinical testing.
Researchers are developing a vaccine to counteract opioid addiction, with the goal of helping people stop the addiction and regain control of their lives. The vaccine, consisting of one shot and two boosters, aims to develop antibodies against opioids, alleviating symptoms and potentially saving lives during overdose.
Researchers developed a DNA vaccine for Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) that completely protects against lethal infection in ferrets. The vaccine induces both neutralizing antibody response and multifunctional T cell immunity.
A new study has gained insights into the mechanism of vaccine-induced T cell immunity, shedding light on the regulation, gene expression, and metabolic pathways of T cells. The discovery of a marker, TfR1, suggests that T cell immunity depends on specific metabolites.
Researchers have achieved a major breakthrough in developing a thermally stable TB vaccine using a technique called ensilication, which protects vaccine components from heat damage. This innovation has the potential to improve the effectiveness and accessibility of vaccines globally, particularly in remote areas.
A novel RSV vaccine candidate, DS-Cav1, has shown early promise in a Phase 1 clinical trial, prompting large increases in RSV-neutralizing antibodies. The vaccine induced a sevenfold increase in neutralizing antibody levels after a single dose of 50 μg and a 12-fold surge with a dose of 150 μg.
Researchers at Yale University have developed a promising combination immune therapy to dramatically reduce the recurrence of genital herpes. The prime-and-pull strategy involves a vaccine and medicated cream that work together to block the virus from spreading.
A large-scale analysis of over 200,000 individuals found no positive correlation between vaccinations and the development of multiple sclerosis. MS patients were statistically less likely to receive vaccinations before diagnosis than comparator groups.
A new, more effective influenza vaccine is being tested in the US, aiming to improve seasonal flu shot effectiveness. The vaccine uses adjuvants to enhance protection against infection, with a technology designed by artificial intelligence.
Researchers developed a new vaccine, NOMV-FHbp, which induced higher levels of protective antibodies than licensed vaccines against five of six bacterial strains. The vaccine has the potential to extend coverage to infants and toddlers, who are at high risk of developing meningococcal disease.
Researchers developed a cancer vaccine technology using live, attenuated pathogens as vectors. The novel vaccine causes the bacteria to self-destruct once they've done their job, making it safe for human use. This innovation has potential applications in treating various cancers and infectious diseases.
Researchers developed a novel mouse model of intestinal parasite infection that mimics human disease, offering protection against Cryptosporidium infection. The model uses a naturally occurring species of mouse Cryptosporidium and demonstrates the importance of T cells and interferon-gamma in immune response.
Researchers have discovered an antibody that can bind to a highly conserved region of the virus, potentially neutralizing all GII.4 strains of norovirus. This breakthrough is a significant step forward in the development of an effective vaccine for the dreaded stomach virus.
Researchers identified factors contributing to placental transfer of antibodies, including a preference for NK-activating antibodies that activate natural killer cells. This knowledge can be used to develop more effective maternal vaccines and deliver them during pregnancy to protect newborns from serious diseases like polio.
Researchers sequenced DNA of over 2,000 Group A Streptococcus samples from 22 countries to identify common genetic targets for a global vaccine. The study reveals that current vaccine candidates may have limited coverage in low-income areas where Strep A is most prevalent.
Scientists have developed a new single vaccination approach that simultaneously protects against both influenza and pneumococcal infections, overcoming the limitations of current vaccines. The approach combines vaccines targeting different components of the virus and bacteria, inducing enhanced cross-protective immunity.
A broadly effective dengue vaccine is still a substantial challenge due to the disease's complexity. However, experts suggest that rethinking existing concepts and developing live attenuated vaccines could lead to more effective solutions.